



Clinical trial results:

A Phase 2, Double-blind, Randomized Study of BGB-290 Versus Placebo as Maintenance Therapy in Patients With Inoperable Locally Advanced or Metastatic Gastric Cancer That Responded to Platinum-based First-line Chemotherapy

Summary

EudraCT number	2017-003493-13
Trial protocol	GB ES HU BE PL CZ
Global end of trial date	03 January 2023

Results information

Result version number	v1 (current)
This version publication date	09 September 2023
First version publication date	09 September 2023

Trial information

Trial identification

Sponsor protocol code	BGB-290-303
-----------------------	-------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03427814
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	BeiGene
Sponsor organisation address	1840 Gateway Drive, San Mateo, CA , United States, 94404
Public contact	Clinical Trial Information Email, BeiGene Ltd., +1 781801 1800, clinicaltrials@beigene.com
Scientific contact	Clinical Trial Information Email, BeiGene Ltd., +1 781801 1800, clinicaltrials@beigene.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	03 January 2023
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	03 January 2023
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To evaluate the efficacy of maintenance therapy with BGB-290 versus placebo in patients with inoperable locally advanced or metastatic gastric cancer with a complete response (CR) or confirmed partial response (PR) after first-line platinum-based chemotherapy, as measured by: Progression-free survival (PFS) by Investigator

Protection of trial subjects:

This study was conducted in accordance with the ethical principles that have their origins in the Declaration of Helsinki and in accordance with BeiGene procedures, which comply with the principles of GCP, International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use guidelines, the Declaration of Helsinki, and local regulatory requirements

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	03 July 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 4
Country: Number of subjects enrolled	Spain: 19
Country: Number of subjects enrolled	United Kingdom: 4
Country: Number of subjects enrolled	Belgium: 4
Country: Number of subjects enrolled	Czechia: 1
Country: Number of subjects enrolled	France: 20
Country: Number of subjects enrolled	Hungary: 3
Country: Number of subjects enrolled	Australia: 6
Country: Number of subjects enrolled	China: 19
Country: Number of subjects enrolled	Georgia: 2
Country: Number of subjects enrolled	Hong Kong: 1
Country: Number of subjects enrolled	Japan: 11
Country: Number of subjects enrolled	Russian Federation: 29
Country: Number of subjects enrolled	Singapore: 1
Country: Number of subjects enrolled	Taiwan: 1
Country: Number of subjects enrolled	United States: 11
Worldwide total number of subjects	136
EEA total number of subjects	51

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	74
From 65 to 84 years	61
85 years and over	1

Subject disposition

Recruitment

Recruitment details:

Subjects were enrolled in multiple study centers in Asia, Australia, Europe, and North America.

Pre-assignment

Screening details:

Screening period was -28 to -1 days prior to first dose

Period 1

Period 1 title	Overall period (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Pamiparib

Arm description:

Participants received 60 milligrams (mg) pamiparib orally twice a day until progressive disease, unacceptable toxicity, death, withdrawal of consent for study treatment, investigator's discretion, start of new anticancer therapy, or Sponsor's decision to end the study.

Arm type	Experimental
Investigational medicinal product name	Pamiparib
Investigational medicinal product code	
Other name	BGB-290
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

60 milligrams (mg) orally, twice daily

Arm title	Placebo
------------------	---------

Arm description:

Participants received 60 mg placebo orally twice daily until progressive disease, unacceptable toxicity, death, withdrawal of consent for study treatment, investigator's discretion, start of new anticancer therapy, or Sponsor's decision to end the study

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

60 mg placebo orally twice daily

Number of subjects in period 1	Pamiparib	Placebo
Started	71	65
Completed	0	0
Not completed	71	65
Consent withdrawn by subject	4	4
Sponsor's Decision	1	-
Investigator's Decision	1	2
Death	42	31
Treatment Completed	-	1
Sponsor's Decision to End Study	21	25
Transfer to Long Term Extension	1	-
Lost to follow-up	-	2
Disease Progression	1	-

Baseline characteristics

Reporting groups

Reporting group title	Pamiparib
-----------------------	-----------

Reporting group description:

Participants received 60 milligrams (mg) pamiparib orally twice a day until progressive disease, unacceptable toxicity, death, withdrawal of consent for study treatment, investigator's discretion, start of new anticancer therapy, or Sponsor's decision to end the study.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Participants received 60 mg placebo orally twice daily until progressive disease, unacceptable toxicity, death, withdrawal of consent for study treatment, investigator's discretion, start of new anticancer therapy, or Sponsor's decision to end the study

Reporting group values	Pamiparib	Placebo	Total
Number of subjects	71	65	136
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean	62.5	62.1	
standard deviation	± 9.8	± 11.23	-
Gender categorical			
Units: Subjects			
Female	25	20	45
Male	46	45	91

End points

End points reporting groups

Reporting group title	Pamiparib
-----------------------	-----------

Reporting group description:

Participants received 60 milligrams (mg) pamiparib orally twice a day until progressive disease, unacceptable toxicity, death, withdrawal of consent for study treatment, investigator's discretion, start of new anticancer therapy, or Sponsor's decision to end the study.

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Participants received 60 mg placebo orally twice daily until progressive disease, unacceptable toxicity, death, withdrawal of consent for study treatment, investigator's discretion, start of new anticancer therapy, or Sponsor's decision to end the study

Primary: Progression Free Survival (PFS) by Investigator Assessment

End point title	Progression Free Survival (PFS) by Investigator Assessment
-----------------	--

End point description:

PFS, is defined as the time from randomization to progressive disease (PD) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 by investigator assessment or death due to any cause, whichever occurs first.

Intent-To-Treat (ITT) Analysis Set is defined as all randomized subjects who are assigned to study drug (pamiparib or placebo).

End point type	Primary
----------------	---------

End point timeframe:

Approximately 23 months

End point values	Pamiparib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	71	65		
Units: Months				
median (confidence interval 95%)	3.7 (1.94 to 5.26)	2.1 (1.87 to 3.75)		

Statistical analyses

Statistical analysis title	Satirical analysis 1
----------------------------	----------------------

Comparison groups	Pamiparib v Placebo
-------------------	---------------------

Number of subjects included in analysis	136
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.1428 ^[1]
Method	Logrank

Notes:

[1] - The one-sided p-value was based on a stratified log-rank test.

Secondary: Overall Survival (OS)

End point title	Overall Survival (OS)
End point description: OS is defined as the time from randomization to death due to any cause. ITT Analysis Set	
End point type	Secondary
End point timeframe: Approximately 23 months	

End point values	Pamiparib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	71	65 ^[2]		
Units: Months				
median (confidence interval 95%)	10.2 (8.71 to 16.33)	12.0 (8.21 to 9999)		

Notes:

[2] - 9999 = Not Estimable due to insufficient number of events

Statistical analyses

No statistical analyses for this end point

Secondary: Time To Second Subsequent Treatment (TSST)

End point title	Time To Second Subsequent Treatment (TSST)
End point description: TSST is defined as the time from randomization until the second subsequent anticancer therapy or death after next-line therapy. ITT Analysis Set	
End point type	Secondary
End point timeframe: Approximately 23 months	

End point values	Pamiparib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	71	65		
Units: Months				
median (confidence interval 95%)	9.8 (8.05 to 10.94)	9.7 (7.49 to 14.00)		

Statistical analyses

No statistical analyses for this end point

Secondary: Objective Response Rate (ORR)

End point title	Objective Response Rate (ORR)
-----------------	-------------------------------

End point description:

ORR is defined as the percentage of participants with a best overall response of Complete Response or Partial Response per RECIST Version 1.1 by investigator assessment

Efficacy Evaluable Analysis Set includes all randomized participants who had measurable disease at baseline and had at least one post baseline tumor assessment unless discontinued treatment due to clinical progression or death prior to tumor assessment

End point type	Secondary
----------------	-----------

End point timeframe:

Approximately 23 months

End point values	Pamiparib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	39	32		
Units: Percentage of participants				
number (confidence interval 95%)	7.7 (1.62 to 20.87)	6.3 (0.77 to 20.81)		

Statistical analyses

No statistical analyses for this end point

Secondary: Duration of Response (DOR)

End point title	Duration of Response (DOR)
-----------------	----------------------------

End point description:

DOR, is defined as the time from the first documented confirmed response of CR or PR to progressive disease (PD) per RECIST Version 1.1 by investigator assessment or death due to any cause, whichever occurs first.

Efficacy Evaluable Analysis Set; Only responders were included in the analysis.

End point type	Secondary
----------------	-----------

End point timeframe:

Approximately 23 months

End point values	Pamiparib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3 ^[3]	2 ^[4]		
Units: Months				
median (confidence interval 95%)	3.6 (3.48 to 9999)	9999 (5.55 to 9999)		

Notes:

[3] - 9999 = Not estimable due to insufficient number of events

[4] - 9999 = Not estimable due to insufficient number of events

Statistical analyses

No statistical analyses for this end point

Secondary: Time To Response

End point title	Time To Response
End point description:	
Time to response is defined as the time from randomization to the first documented response of CR or PR per RECIST Version 1.1 by investigator assessment. Efficacy Evaluable Analysis Set; Only responders were included in the analysis.	
End point type	Secondary
End point timeframe:	
Approximately 23 months	

End point values	Pamiparib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	3	2		
Units: Months				
median (confidence interval 95%)	3.68 (1.8 to 7.3)	1.87 (1.87 to 1.9)		

Statistical analyses

No statistical analyses for this end point

Secondary: Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

End point title	Number of Participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
End point description:	
Safety Analysis Set includes all participants in the ITT Analysis Set who receive at least one dose of study treatment (pamiparib or placebo).	
End point type	Secondary
End point timeframe:	
From start of study treatment until 30 days after the last study drug intake or initiation of new anticancer therapy, whichever occurs first (up to approximately 4 years and 5.5 months)	

End point values	Pamiparib	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	71	65		
Units: Number of participants				
Participant With At Least 1 TEAE	66	61		
Participants with Serious TEAEs	17	11		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From start of study treatment until 30 days after the last study drug intake or initiation of new anticancer therapy, whichever occurs first

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	25
--------------------	----

Reporting groups

Reporting group title	Placebo
-----------------------	---------

Reporting group description:

Participants received 60 mg placebo orally twice daily until progressive disease, unacceptable toxicity, death, withdrawal of consent for study treatment, investigator's discretion, start of new anticancer therapy, or Sponsor's decision to end the study

Reporting group title	Pamiparib 60 mg BID
-----------------------	---------------------

Reporting group description:

Participants received 60 milligrams (mg) pamiparib orally twice a day until progressive disease, unacceptable toxicity, death, withdrawal of consent for study treatment, investigator's discretion, start of new anticancer therapy, or Sponsor's decision to end the study.

Serious adverse events	Placebo	Pamiparib 60 mg BID	
Total subjects affected by serious adverse events			
subjects affected / exposed	11 / 65 (16.92%)	17 / 71 (23.94%)	
number of deaths (all causes)	31	42	
number of deaths resulting from adverse events	2	3	
Investigations			
Platelet count decreased			
subjects affected / exposed	0 / 65 (0.00%)	1 / 71 (1.41%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Hepatic rupture			
subjects affected / exposed	1 / 65 (1.54%)	0 / 71 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Vascular disorders			
Hypotension			

subjects affected / exposed	0 / 65 (0.00%)	1 / 71 (1.41%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 65 (1.54%)	3 / 71 (4.23%)	
occurrences causally related to treatment / all	1 / 1	1 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Death			
subjects affected / exposed	0 / 65 (0.00%)	2 / 71 (2.82%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 2	
General physical health deterioration			
subjects affected / exposed	0 / 65 (0.00%)	1 / 71 (1.41%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 65 (0.00%)	1 / 71 (1.41%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			
subjects affected / exposed	3 / 65 (4.62%)	0 / 71 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal obstruction			
subjects affected / exposed	0 / 65 (0.00%)	1 / 71 (1.41%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	1 / 65 (1.54%)	0 / 71 (0.00%)	
occurrences causally related to treatment / all	2 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Malignant dysphagia			
subjects affected / exposed	1 / 65 (1.54%)	0 / 71 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Subileus			
subjects affected / exposed	0 / 65 (0.00%)	1 / 71 (1.41%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Obstruction gastric			
subjects affected / exposed	2 / 65 (3.08%)	0 / 71 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 65 (1.54%)	1 / 71 (1.41%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	0 / 65 (0.00%)	2 / 71 (2.82%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Jaundice			
subjects affected / exposed	0 / 65 (0.00%)	1 / 71 (1.41%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Pleural effusion			
subjects affected / exposed	0 / 65 (0.00%)	1 / 71 (1.41%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonitis			
subjects affected / exposed	0 / 65 (0.00%)	1 / 71 (1.41%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Psychiatric disorders			
Depression			
subjects affected / exposed	0 / 65 (0.00%)	1 / 71 (1.41%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Renal colic			
subjects affected / exposed	0 / 65 (0.00%)	1 / 71 (1.41%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Postrenal failure			
subjects affected / exposed	1 / 65 (1.54%)	0 / 71 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute kidney injury			
subjects affected / exposed	0 / 65 (0.00%)	1 / 71 (1.41%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Pneumocystis jirovecii infection			
subjects affected / exposed	0 / 65 (0.00%)	1 / 71 (1.41%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Device related infection			
subjects affected / exposed	0 / 65 (0.00%)	1 / 71 (1.41%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	1 / 65 (1.54%)	0 / 71 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	1 / 1	0 / 0	
Pneumonia			

subjects affected / exposed	1 / 65 (1.54%)	2 / 71 (2.82%)	
occurrences causally related to treatment / all	1 / 1	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 1	

Frequency threshold for reporting non-serious adverse events: 3 %

Non-serious adverse events	Placebo	Pamiparib 60 mg BID	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	57 / 65 (87.69%)	65 / 71 (91.55%)	
Investigations			
Blood alkaline phosphatase increased			
subjects affected / exposed	4 / 65 (6.15%)	6 / 71 (8.45%)	
occurrences (all)	6	6	
Aspartate aminotransferase increased			
subjects affected / exposed	5 / 65 (7.69%)	9 / 71 (12.68%)	
occurrences (all)	6	11	
Alanine aminotransferase increased			
subjects affected / exposed	5 / 65 (7.69%)	8 / 71 (11.27%)	
occurrences (all)	6	9	
Blood bilirubin increased			
subjects affected / exposed	1 / 65 (1.54%)	3 / 71 (4.23%)	
occurrences (all)	2	4	
Blood creatinine increased			
subjects affected / exposed	2 / 65 (3.08%)	5 / 71 (7.04%)	
occurrences (all)	2	5	
Platelet count decreased			
subjects affected / exposed	2 / 65 (3.08%)	8 / 71 (11.27%)	
occurrences (all)	3	10	
Neutrophil count decreased			
subjects affected / exposed	3 / 65 (4.62%)	7 / 71 (9.86%)	
occurrences (all)	4	17	
Lymphocyte count decreased			
subjects affected / exposed	1 / 65 (1.54%)	4 / 71 (5.63%)	
occurrences (all)	3	4	
Blood lactate dehydrogenase			

increased subjects affected / exposed occurrences (all)	3 / 65 (4.62%) 3	4 / 71 (5.63%) 4	
Weight increased subjects affected / exposed occurrences (all)	2 / 65 (3.08%) 2	0 / 71 (0.00%) 0	
White blood cell count decreased subjects affected / exposed occurrences (all)	3 / 65 (4.62%) 6	8 / 71 (11.27%) 16	
Weight decreased subjects affected / exposed occurrences (all)	2 / 65 (3.08%) 2	9 / 71 (12.68%) 9	
Vascular disorders			
Hypertension subjects affected / exposed occurrences (all)	2 / 65 (3.08%) 3	2 / 71 (2.82%) 3	
Hypotension subjects affected / exposed occurrences (all)	0 / 65 (0.00%) 0	5 / 71 (7.04%) 5	
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	0 / 65 (0.00%) 0	3 / 71 (4.23%) 3	
Headache subjects affected / exposed occurrences (all)	2 / 65 (3.08%) 2	2 / 71 (2.82%) 2	
Dysgeusia subjects affected / exposed occurrences (all)	2 / 65 (3.08%) 2	6 / 71 (8.45%) 6	
Paraesthesia subjects affected / exposed occurrences (all)	3 / 65 (4.62%) 4	1 / 71 (1.41%) 2	
Peripheral sensory neuropathy subjects affected / exposed occurrences (all)	9 / 65 (13.85%) 10	4 / 71 (5.63%) 4	
Blood and lymphatic system disorders			

Leukopenia			
subjects affected / exposed	1 / 65 (1.54%)	3 / 71 (4.23%)	
occurrences (all)	1	5	
Lymphopenia			
subjects affected / exposed	0 / 65 (0.00%)	4 / 71 (5.63%)	
occurrences (all)	0	4	
Neutropenia			
subjects affected / exposed	3 / 65 (4.62%)	5 / 71 (7.04%)	
occurrences (all)	4	8	
Thrombocytopenia			
subjects affected / exposed	5 / 65 (7.69%)	4 / 71 (5.63%)	
occurrences (all)	7	7	
Anaemia			
subjects affected / exposed	10 / 65 (15.38%)	25 / 71 (35.21%)	
occurrences (all)	12	31	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	12 / 65 (18.46%)	16 / 71 (22.54%)	
occurrences (all)	12	16	
Chest pain			
subjects affected / exposed	0 / 65 (0.00%)	3 / 71 (4.23%)	
occurrences (all)	0	5	
Fatigue			
subjects affected / exposed	4 / 65 (6.15%)	4 / 71 (5.63%)	
occurrences (all)	4	4	
Pyrexia			
subjects affected / exposed	1 / 65 (1.54%)	6 / 71 (8.45%)	
occurrences (all)	1	6	
Oedema peripheral			
subjects affected / exposed	4 / 65 (6.15%)	5 / 71 (7.04%)	
occurrences (all)	4	5	
Malaise			
subjects affected / exposed	2 / 65 (3.08%)	4 / 71 (5.63%)	
occurrences (all)	2	4	
Gastrointestinal disorders			

Abdominal distension			
subjects affected / exposed	3 / 65 (4.62%)	4 / 71 (5.63%)	
occurrences (all)	3	5	
Dysphagia			
subjects affected / exposed	7 / 65 (10.77%)	3 / 71 (4.23%)	
occurrences (all)	7	3	
Diarrhoea			
subjects affected / exposed	9 / 65 (13.85%)	13 / 71 (18.31%)	
occurrences (all)	10	21	
Constipation			
subjects affected / exposed	9 / 65 (13.85%)	9 / 71 (12.68%)	
occurrences (all)	9	13	
Abdominal pain upper			
subjects affected / exposed	7 / 65 (10.77%)	12 / 71 (16.90%)	
occurrences (all)	7	13	
Abdominal pain			
subjects affected / exposed	13 / 65 (20.00%)	9 / 71 (12.68%)	
occurrences (all)	14	9	
Gastrooesophageal reflux disease			
subjects affected / exposed	3 / 65 (4.62%)	4 / 71 (5.63%)	
occurrences (all)	3	4	
Stomatitis			
subjects affected / exposed	3 / 65 (4.62%)	3 / 71 (4.23%)	
occurrences (all)	3	4	
Odynophagia			
subjects affected / exposed	2 / 65 (3.08%)	1 / 71 (1.41%)	
occurrences (all)	2	1	
Nausea			
subjects affected / exposed	12 / 65 (18.46%)	23 / 71 (32.39%)	
occurrences (all)	14	26	
Vomiting			
subjects affected / exposed	2 / 65 (3.08%)	16 / 71 (22.54%)	
occurrences (all)	2	17	
Respiratory, thoracic and mediastinal disorders			

Cough subjects affected / exposed occurrences (all)	2 / 65 (3.08%) 2	3 / 71 (4.23%) 3	
Dysphonia subjects affected / exposed occurrences (all)	2 / 65 (3.08%) 2	0 / 71 (0.00%) 0	
Dyspnoea subjects affected / exposed occurrences (all)	2 / 65 (3.08%) 2	2 / 71 (2.82%) 2	
Rhinorrhoea subjects affected / exposed occurrences (all)	3 / 65 (4.62%) 3	0 / 71 (0.00%) 0	
Skin and subcutaneous tissue disorders			
Onycholysis subjects affected / exposed occurrences (all)	2 / 65 (3.08%) 2	0 / 71 (0.00%) 0	
Dry skin subjects affected / exposed occurrences (all)	0 / 65 (0.00%) 0	3 / 71 (4.23%) 3	
Pruritus subjects affected / exposed occurrences (all)	2 / 65 (3.08%) 2	0 / 71 (0.00%) 0	
Psychiatric disorders			
Insomnia subjects affected / exposed occurrences (all)	5 / 65 (7.69%) 5	3 / 71 (4.23%) 3	
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	3 / 65 (4.62%) 3	7 / 71 (9.86%) 8	
Myalgia subjects affected / exposed occurrences (all)	2 / 65 (3.08%) 2	1 / 71 (1.41%) 1	
Musculoskeletal chest pain subjects affected / exposed occurrences (all)	2 / 65 (3.08%) 2	0 / 71 (0.00%) 0	

Muscle spasms subjects affected / exposed occurrences (all)	2 / 65 (3.08%) 2	1 / 71 (1.41%) 1	
Back pain subjects affected / exposed occurrences (all)	7 / 65 (10.77%) 7	3 / 71 (4.23%) 3	
Infections and infestations			
Gastroenteritis viral subjects affected / exposed occurrences (all)	2 / 65 (3.08%) 2	0 / 71 (0.00%) 0	
Upper respiratory tract infection subjects affected / exposed occurrences (all)	2 / 65 (3.08%) 3	4 / 71 (5.63%) 5	
Pneumonia subjects affected / exposed occurrences (all)	2 / 65 (3.08%) 2	0 / 71 (0.00%) 0	
Nasopharyngitis subjects affected / exposed occurrences (all)	2 / 65 (3.08%) 2	0 / 71 (0.00%) 0	
Metabolism and nutrition disorders			
Decreased appetite subjects affected / exposed occurrences (all)	9 / 65 (13.85%) 11	19 / 71 (26.76%) 21	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
13 February 2020	<p>Changed from Phase 3 to Phase 2</p> <p>Decreased the planned enrollment from 540 patients (Phase 3) to 128 patients (Phase 2)</p> <p>Changed PFS assessment by Blinded Independent Review Committee (Phase 3) to investigator assessed (Phase 2)</p> <p>Design was changed to provide 80% power for measuring PFS (Phase 2), instead of 90% power for measures of PFS and overall survival (Phase 3)</p> <p>Timing of final PFS analysis planned to occur when 85 PFS events had occurred (Phase 2), reduced from 363 PFS event (ie, 66% of the reduced target sample size) (Phase 3)</p> <p>Interim analysis was removed</p> <p>Provisions added to continue providing study drug to patients who received blinded pamiparib after unblinding</p> <p>Added provisions for emergency unblinding of a patient's treatment assignment at the investigator's discretion, per request by Regulatory Health Authority</p> <p>Reduced planned study duration from 3.5 years (Phase 3) to 2.5 years (Phase 2)</p> <p>Increased the safety precautions to reduce risk of pregnancies by requiring female partners of nonsterile male study patients to agree to practice highly effective methods of birth control and add limitation on sperm donation after last study drug administration.</p>

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported